The DOI matches its Crossref record.
Adverse events associated with itraconazole in 189 patients on chronic therapy
Open accessAbstract
Itraconazole was administered at doses of 50-400 mg/day to 189 patients with a variety of systemic mycoses for a median of five months. Adverse reactions possibly due to itraconazole were seen in 74 patients (39%). Mild gastrointestinal reactions were most common; other reactions including hypertriglyceridaemia, hypokalaemia and liver enzyme elevations occurred less frequently. No fatal reactions have been noted and toxicity has rarely led to a discontinuation of therapy. Chronic therapy with itraconazole appears well tolerated by the majority of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss, R., Denning, D. W., & ABPA complicating asthma ISHAM working group (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12141 · Cited by 896
Self-citationStevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790
Self-citationThe biology and chemistry of antifungal agents: A review
Kathiravan, M. K., Salake, A. B., Chothe, A. S., Dudhe, P. B., Watode, R. P., Mukta, M. S., & Gadhwe, S. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.04.045 · Cited by 664
Oral Azole Drugs as Systemic Antifungal Therapy
Wood, A. J. J., Como, J. A., & Dismukes, W. E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300407 · Cited by 596
A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis
Stevens, D. A., Schwartz, H. J., Lee, J. Y., Moskovitz, B. L., Jerome, D. C., Catanzaro, A., Bamberger, D. M., Weinmann, A. J., Tuazon, C. U., Judson, M. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421102 · Cited by 533
Self-citationAllergic Bronchopulmonary Aspergillosis
Agarwal, R. (2009) · Chest · doi:10.1378/chest.08-2586 · Cited by 407
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Antifungal agents: An overview. Part I
Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81495-8 · Cited by 369
Itraconazole therapy for blastomycosis and histoplasmosis
Dismukes, W. E., Bradsher, R. W., Cloud, G. C., Kauffman, C. A., Chapman, S. W., George, R. B., Stevens, D. A., Girard, W. M., Saag, M. S., & Bowles-Patton, C. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90575-v · Cited by 310
Self-citationSevere asthma with fungal sensitization
Agarwal, R. (2011) · Current Allergy and Asthma Reports · doi:10.1007/s11882-011-0217-4 · Cited by 188
“Itraconazole also has a myriad of side effects, which in different studies have affected a range of 19%–39% of patients [107, 108].”
BackgroundGroll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2554-2563.2002 · Cited by 123
Itraconazole: pharmacology, clinical experience and future development
De Beule, K. (1996) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00043-7 · Cited by 96
Chronic Pulmonary Aspergillosis—Where Are We? and Where Are We Going?
Hayes, G., & Novak-Frazer, L. (2016) · Journal of Fungi · doi:10.3390/jof2020018 · Cited by 77
Metadata
- Authors
- Tucker, R. M., Haq, Y., Denning, D. W., & Stevens, D. A.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1990
- Volume
- 26
- Issue
- 4
- Pages
- 561-566
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2076053525
- Cited by
- 199
- References
- 0
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.